{"disease":{"id":"recurrent-hepatocellular-carcinoma","name":"recurrent hepatocellular carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06233708","title":"Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":2092,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT01015833","title":"Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03186898","title":"Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01963429","title":"Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC","phase":"NA","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04663035","title":"Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Ming Zhao","has_results":false},{"nct_id":"NCT06609850","title":"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03609268","title":"Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04615143","title":"Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04800497","title":"The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT02423343","title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT01900002","title":"Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02143401","title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06968195","title":"Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05103904","title":"Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02762266","title":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04805788","title":"Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03655002","title":"IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02013492","title":"Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"William Carson","has_results":false},{"nct_id":"NCT05327738","title":"Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}